How to Get Vyleesi in New Jersey

What Is Vyleesi and Why Does It Require a Prescription?

Bremelanotide, sold under the brand name Vyleesi, is a melanocortin receptor agonist that acts on MC1R and MC4R pathways in the central nervous system to increase sexual desire. The FDA approved it on June 21, 2019, for generalized, acquired HSDD in premenopausal women. Vyleesi FDA prescribing information is available on the FDA label database.

How Bremelanotide Differs from Flibanserin

Vyleesi is an on-demand injection taken 45 minutes before anticipated sexual activity. Flibanserin (Addyi), the other FDA-approved HSDD drug, is a daily oral tablet. The two drugs work through entirely different receptor systems. Because bremelanotide transiently raises blood pressure by an average of 2 to 4 mmHg in clinical trials, the FDA label carries a specific warning against use in patients with cardiovascular disease.

Efficacy Data from RECONNECT

The RECONNECT trial program, published in Obstetrics and Gynecology in 2019, was the primary evidence basis for FDA approval. In the two integrated Phase 3 trials (combined N=1,267), bremelanotide produced statistically significant improvements in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm total score compared with placebo (P<0.001 for both co-primary endpoints). Responder rates for a clinically meaningful change in desire were approximately 25% for bremelanotide versus 17% for placebo.

The trial also measured the proportion of women who reported at least one additional satisfying sexual event per month. Bremelanotide-treated participants gained a mean of 0.7 additional satisfying sexual events per month versus 0.3 in the placebo arm.

Who Can Prescribe Vyleesi in New Jersey?

Any licensed prescriber with authority to write Schedule-uncontrolled prescription medications in New Jersey may prescribe bremelanotide. That includes physicians (MD or DO), nurse practitioners (NPs), and physician assistants (PAs) operating within their scope of practice under New Jersey statutes. The New Jersey Division of Consumer Affairs outlines advanced practice nurse prescriptive authority under N.J.S.A. 45:11-49.

Specialists Most Likely to Prescribe

OB-GYNs, reproductive endocrinologists, sexual medicine specialists, and psychiatrists with a focus on women's health are the most common prescribers. Some primary care physicians familiar with the RECONNECT data also prescribe it. The key requirement is that the clinician performs an adequate HSDD assessment, which includes ruling out relationship distress, medication-induced low desire (SSRIs are a frequent culprit), and hormonal causes such as low estradiol or androgen insufficiency.

Can a Telehealth Provider in New Jersey Prescribe Vyleesi?

Yes. New Jersey permits telehealth prescribing for non-controlled substances after the establishment of a valid patient-provider relationship via synchronous audio-video encounter. Bremelanotide is not a controlled substance, so no in-person visit is legally required before the first prescription. The New Jersey Telemedicine and Telehealth Act (N.J.S.A. 45:1-62) governs this. Platforms that specialize in women's sexual health routinely complete intake, assessment, and prescription in a single visit.

Step-by-Step: How to Get a Vyleesi Prescription in New Jersey

Getting bremelanotide in New Jersey follows a predictable clinical pathway regardless of whether you use telehealth or an in-office provider.

Step 1. Confirm You Meet the Indication

The FDA-approved indication is generalized, acquired HSDD in premenopausal women. "Generalized" means low desire occurs across all situations, not just with a specific partner. "Acquired" means desire was normal at some earlier point. A validated screening tool, the Decreased Sexual Desire Screener (DSDS), takes under five minutes and is often administered electronically before the visit. The DSDS was validated in a 2010 study published in the Journal of Sexual Medicine.

Step 2. Book a Telehealth or In-Office Visit

Telehealth options include HealthRX and several competing platforms. In-office options include academic medical centers such as Rutgers Robert Wood Johnson Medical School's OB-GYN department, private OB-GYN practices across Bergen, Essex, Middlesex, and Monmouth counties, and sexual medicine specialists in Newark and Princeton. Book an appointment labeled "women's sexual health" or "HSDD consultation."

Step 3. Complete the Clinical Assessment

During the visit, the clinician will:

• Administer or review the DSDS or Female Sexual Function Index (FSFI)
• Obtain a resting blood pressure reading (a single elevated reading above 130/80 mmHg warrants further evaluation before prescribing)
• Review your current medication list for desire-suppressing agents, particularly SSRIs, SNRIs, oral contraceptives, and antihistamines
• Screen for depressive disorder, relationship distress, and thyroid dysfunction

The Endocrine Society's clinical practice guideline on female sexual dysfunction recommends ruling out androgen deficiency and estrogen insufficiency before attributing low desire to primary HSDD.

Step 4. Receive and Fill the Prescription

The prescription may be sent to a retail pharmacy, a specialty pharmacy, or a licensed 503A compounding pharmacy. Patients using commercial insurance often direct the prescription to a specialty pharmacy that handles prior authorization processing. Cash-pay patients frequently use 503A compounding pharmacies to reduce cost.

Lab Requirements Before Starting Vyleesi in New Jersey

Vyleesi does not require the same pre-treatment laboratory panel as flibanserin, which mandates a liver function assessment due to its CYP2C19 interaction profile. For bremelanotide, the clinical requirements are narrower.

Required Assessment

A single resting blood pressure reading is the minimum required safety check. The FDA label for bremelanotide contraindicates use in patients with known cardiovascular disease, including uncontrolled hypertension.

Recommended but Not Mandated

Many prescribers also order:

• TSH to rule out hypothyroidism as a driver of low libido
• Free testosterone and SHBG if androgen insufficiency is suspected
• Fasting glucose or HbA1c in women with metabolic risk factors
• Estradiol in perimenopausal women where the distinction from true premenopause is clinically relevant

A 2021 review in the Journal of Women's Health noted that approximately 30% of women presenting with HSDD symptoms have an identifiable hormonal or medical cause that, when treated, resolves low desire without need for bremelanotide. Ordering baseline labs saves patients a second prescription and an unnecessary drug trial.

Blood Pressure Monitoring at Home

Because each injection transiently raises blood pressure, women with borderline hypertension should have a home blood pressure cuff before beginning therapy. The prescriber may request a log of 5 to 7 readings at different times of day. A 2019 pharmacokinetic analysis confirmed that the mean peak blood pressure increase after a single 1.75 mg dose occurs within 4 to 12 hours and resolves within 12 hours in most participants.

Insurance Coverage and Prior Authorization in New Jersey

NJ Medicaid

New Jersey Medicaid (NJ FamilyCare) covers Vyleesi for premenopausal women with HSDD when prior authorization (PA) criteria are met. CMS guidance on Medicaid coverage of FDA-approved drugs for women's health is available at CMS.gov.

The standard PA package for NJ Medicaid requires:

• Written HSDD diagnosis using DSM-5 criteria (code F52.0)
• Documentation that the low desire causes personal distress (a completed FSFI or DSDS score supports this)
• Confirmation of premenopausal status (FSH level or clinical documentation)
• Attestation that the patient has been counseled about non-pharmacologic options

Approvals typically take 5 to 14 business days. Some prescribers submit a peer-to-peer appeal if initial PA is denied, which shortens the timeline.

Commercial Insurance

Commercial plan coverage varies. Larger carriers in New Jersey, including Horizon Blue Cross Blue Shield of New Jersey and Aetna plans sold through the NJ marketplace, sometimes cover Vyleesi under pharmacy benefits with a PA. Step therapy requirements vary by plan. Some plans require documentation that the patient has tried and failed a course of psychotherapy or sex therapy before bremelanotide is approved.

Prior Authorization Documentation Checklist

Clinicians and patients assembling a PA request for Vyleesi in New Jersey should gather:

1. ICD-10 code F52.0 (hypoactive sexual desire dysfunction) on the prescriber's letterhead
2. Completed DSDS or FSFI with scored results
3. Blood pressure reading dated within 90 days
4. Current medication list documenting absence of contraindicated agents or explanation of clinical rationale for co-prescribing
5. FSH or clinical documentation confirming premenopausal status
6. Brief clinical note (or letter of medical necessity) from the prescriber describing onset, duration, and personal distress
7. For plans requiring step therapy: documentation of previous psychotherapy, couples counseling, or trial of another intervention

Submitting all seven components in the initial PA packet reduces denial rates and eliminates back-and-forth with the insurance reviewer.

503A Compounding Pharmacies and Bremelanotide in New Jersey

What 503A Means for Patients

A 503A compounding pharmacy operates under state pharmacy board authority and may prepare patient-specific compounded medications. These pharmacies are not required to use FDA-approved finished drug products but must comply with USP standards and New Jersey Board of Pharmacy regulations. The FDA's guidance on 503A compounding pharmacies distinguishes them from 503B outsourcing facilities.

Is Compounded Bremelanotide Legal in New Jersey?

Licensed 503A pharmacies in New Jersey may compound bremelanotide for individual patients when a valid prescription is presented from a licensed New Jersey prescriber. The compounded form is often supplied as a multi-dose vial or pre-filled syringe at lower cost than the branded Vyleesi auto-injector. The New Jersey Board of Pharmacy oversees 503A compounding under N.J.A.C. 13:39-11.

Patients using compounded bremelanotide should confirm:

• The pharmacy holds a current New Jersey Board of Pharmacy license
• Peptide raw material has a Certificate of Analysis (CoA) from a third-party laboratory
• Sterility testing has been conducted on each lot

Cost Comparison: Branded vs. Compounded

The brand-name Vyleesi auto-injector retails for approximately $960 to $1,100 for a 4-pack without insurance. Compounded bremelanotide from a licensed 503A pharmacy may cost $150 to $350 for an equivalent supply when paying cash. These figures fluctuate by pharmacy and formulation.

How Long Until Vyleesi Arrives in New Jersey?

Timeline from first contact to first injection varies by pathway.

Telehealth Pathway

• Day 0: Complete intake forms online (10 to 15 minutes)
• Day 0 to 1: Synchronous telehealth visit (20 to 30 minutes)
• Day 0 to 1: Prescription transmitted electronically to pharmacy of choice
• Day 1 to 3: Compounding pharmacy ships or dispenses; retail specialty pharmacy begins PA process
• Day 3 to 7: Medication in hand for most patients using compounding pharmacies or plans with fast PA processing

In-Office Pathway

In-office appointments at academic centers in New Jersey may have 2 to 6 week wait times for new patients. Once prescribed, the pharmacy timeline mirrors the telehealth pathway.

PA Delay Scenarios

When commercial insurance PA is required, total time from visit to medication can stretch to 4 to 6 weeks. Patients who need Vyleesi sooner often pay cash for the first month's supply through a 503A pharmacy while waiting for PA approval to cover future refills.

Transferring a Vyleesi Prescription to New Jersey

Patients who move to New Jersey, or who began treatment in another state and now want to continue, have a straightforward path.

Retail Pharmacy Transfer

Non-controlled prescriptions in New Jersey may be transferred between licensed pharmacies. Call the receiving New Jersey pharmacy, provide the original pharmacy's name and phone number, and the receiving pharmacy handles the transfer. New Jersey pharmacy transfer rules are governed by N.J.A.C. 13:39-7.

Telehealth Re-Evaluation

Some telehealth platforms operating in multiple states maintain medical records across state lines. If your original prescriber is not licensed in New Jersey, a new 20 to 30 minute telehealth visit with a New Jersey-licensed clinician establishes the required prescriber-patient relationship and produces a fresh prescription. Bring records from your prior provider to expedite the assessment.

Insurance Continuity

If you had a PA approval in another state and your insurance plan is a national commercial plan (Aetna, Cigna, UnitedHealthcare), coverage may transfer automatically. Check with your plan's pharmacy benefits team. New Jersey Medicaid requires a new PA tied to a New Jersey prescriber.

Side Effects New Jersey Patients Should Know Before Starting

The Vyleesi FDA prescribing information lists nausea (40.0% of treated patients vs. 1.4% placebo), flushing (20.4% vs. 1.4%), and injection-site bruising (12.5% vs. 10.3%) as the most common adverse events.

Managing Nausea

Nausea typically begins within one hour of injection and resolves within 12 hours. An antiemetic such as ondansetron 4 mg taken 30 minutes before the injection reduces nausea severity in most patients, per the RECONNECT trial's supplementary data. Some prescribers co-prescribe ondansetron ODT (orally disintegrating tablet) with the first several Vyleesi doses.

Transient Hyperpigmentation

Focal hyperpigmentation of the face, gums, or breasts occurs in approximately 1% of patients with chronic use. The FDA label notes this is more common in patients with darker skin tones. Patients who notice new skin darkening should contact their prescriber and suspend injections pending evaluation.

Blood Pressure Monitoring

Every patient should measure blood pressure 4 to 6 hours after the first two or three injections. A reading above 140/90 mmHg that persists beyond 12 hours after injection warrants a call to the prescriber.

Dosing and Administration Reminders for New Jersey Patients

Vyleesi is administered as a single 1.75 mg subcutaneous injection using the pre-filled auto-injector into the abdomen or thigh. It should be taken at least 45 minutes before anticipated sexual activity. No more than one dose per 24-hour period is permitted. The FDA label specifies discontinuing use if no response is seen after 8 weeks of use.

Store the auto-injector at room temperature, away from direct heat. Once removed from the refrigerator (if shipped cold by the pharmacy), the auto-injector is stable for up to 30 days at temperatures below 77°F (25°C).